JP2002535408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002535408A5 JP2002535408A5 JP2000596009A JP2000596009A JP2002535408A5 JP 2002535408 A5 JP2002535408 A5 JP 2002535408A5 JP 2000596009 A JP2000596009 A JP 2000596009A JP 2000596009 A JP2000596009 A JP 2000596009A JP 2002535408 A5 JP2002535408 A5 JP 2002535408A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- hydrogen
- formula
- compound according
- hexahydropyrazino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 31
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- 239000001257 hydrogen Substances 0.000 description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- KRZJRNZICWNMOA-GXSJLCMTSA-N (3s,4r)-4,8-dihydroxy-3-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=CC=C2[C@@H](O)[C@@H](OC)CC(=O)C2=C1O KRZJRNZICWNMOA-GXSJLCMTSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- RQMCYUIGJSZWDQ-SNVBAGLBSA-N (10aR)-8-chloro-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole Chemical compound C1CNC[C@H]2CC3=CC(Cl)=CC=C3N21 RQMCYUIGJSZWDQ-SNVBAGLBSA-N 0.000 description 1
- UONHLVCQYSKINY-SNVBAGLBSA-N (10ar)-7-chloro-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole Chemical compound C1NCCN2C3=CC(Cl)=CC=C3C[C@@H]21 UONHLVCQYSKINY-SNVBAGLBSA-N 0.000 description 1
- ILABBYCXAZPSHM-UHFFFAOYSA-N 7-bromo-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole Chemical compound C1NCCN2C3=CC(Br)=CC=C3CC21 ILABBYCXAZPSHM-UHFFFAOYSA-N 0.000 description 1
- UONHLVCQYSKINY-UHFFFAOYSA-N 7-chloro-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole Chemical compound C1NCCN2C3=CC(Cl)=CC=C3CC21 UONHLVCQYSKINY-UHFFFAOYSA-N 0.000 description 1
- YNABRINHPQKTRU-UHFFFAOYSA-N 7-chloro-8-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole Chemical compound C1C2CNCCN2C2=C1C=C(C)C(Cl)=C2 YNABRINHPQKTRU-UHFFFAOYSA-N 0.000 description 1
- MSHHWMXRKJPFII-UHFFFAOYSA-N 8-chloro-2-methyl-3,4,10,10a-tetrahydro-1h-pyrazino[1,2-a]indole Chemical compound ClC1=CC=C2N3CCN(C)CC3CC2=C1 MSHHWMXRKJPFII-UHFFFAOYSA-N 0.000 description 1
- MRRJCJZEOZZZQL-UHFFFAOYSA-N 9-chloro-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole Chemical compound N12CCNCC2CC2=C1C=CC=C2Cl MRRJCJZEOZZZQL-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000027626 Neurocognitive disease Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 208000025748 atypical depressive disease Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9902047.1A GB9902047D0 (en) | 1999-01-29 | 1999-01-29 | Chemical compounds XI |
| GB9902047.1 | 1999-01-29 | ||
| PCT/GB2000/000244 WO2000044753A1 (en) | 1999-01-29 | 2000-01-28 | Pirazino(aza)indole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002535408A JP2002535408A (ja) | 2002-10-22 |
| JP2002535408A5 true JP2002535408A5 (enExample) | 2007-03-08 |
Family
ID=10846774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000596009A Pending JP2002535408A (ja) | 1999-01-29 | 2000-01-28 | ピラジノ（アザ）インドール誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US6800627B1 (enExample) |
| EP (1) | EP1147110B1 (enExample) |
| JP (1) | JP2002535408A (enExample) |
| KR (1) | KR100633375B1 (enExample) |
| CN (2) | CN1289499C (enExample) |
| AT (1) | ATE239731T1 (enExample) |
| AU (1) | AU758685B2 (enExample) |
| BR (1) | BR0008979A (enExample) |
| CA (1) | CA2359034A1 (enExample) |
| DE (1) | DE60002554T2 (enExample) |
| DK (1) | DK1147110T3 (enExample) |
| ES (1) | ES2199132T3 (enExample) |
| GB (1) | GB9902047D0 (enExample) |
| MX (1) | MXPA01007643A (enExample) |
| PT (1) | PT1147110E (enExample) |
| TR (1) | TR200102161T2 (enExample) |
| WO (1) | WO2000044753A1 (enExample) |
| ZA (1) | ZA200106202B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960579B1 (en) | 1998-05-19 | 2005-11-01 | Alcon Manufacturing, Ltd. | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders |
| FR2799757B1 (fr) * | 1999-10-15 | 2001-12-14 | Adir | Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN1277828C (zh) | 2000-07-31 | 2006-10-04 | 霍夫曼-拉罗奇有限公司 | 哌嗪衍生物 |
| EP1337518B1 (en) | 2000-11-20 | 2009-06-17 | Biovitrum AB (publ) | Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor |
| SE0004245D0 (sv) | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
| HUP0303316A2 (hu) * | 2000-12-20 | 2004-01-28 | Bristol-Myers Squibb Pharma Company | Aril- és amino-aril-szubsztituált szerotoninreceptor agonista és antagonista ligandumok és ezeket tartalmazó gyógyszerkészítmények |
| GB0106177D0 (en) * | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| WO2002098860A1 (en) | 2001-06-01 | 2002-12-12 | Alcon, Inc. | Novel fused indazoles and indoles and their use for the treatment of glaucoma |
| MXPA03010806A (es) | 2001-06-01 | 2004-11-22 | Alcon Inc | Nuevos analogos de arilaminopropano y su uso para el tratamiento de glaucoma. |
| DK1392292T3 (da) | 2001-06-01 | 2006-05-29 | Alcon Inc | Pyranoindazoler og deres anvendelse til behandling af glaukom |
| US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| TW593302B (en) | 2001-12-20 | 2004-06-21 | Alcon Inc | Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma |
| GB0202015D0 (en) * | 2002-01-29 | 2002-03-13 | Hoffmann La Roche | Piperazine Derivatives |
| BR0311970A (pt) | 2002-06-19 | 2005-03-29 | Biovitrum Ab | Novos compostos, seu uso e preparação |
| WO2004054572A2 (en) | 2002-12-13 | 2004-07-01 | Alcon, Inc. | Novel benzopyran analogs and their use for the treatment of glaucoma |
| MXPA05012547A (es) * | 2003-05-21 | 2006-05-25 | Prosidion Ltd | Inhibidores de amida de acido pirrolopiridina-2-carboxilico de fosforilasa de glucogeno. |
| US7405210B2 (en) | 2003-05-21 | 2008-07-29 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
| GB0314967D0 (en) * | 2003-06-26 | 2003-07-30 | Hoffmann La Roche | Piperazine derivatives |
| US7476687B2 (en) | 2003-11-26 | 2009-01-13 | Alcon, Inc. | Substituted furo[2,3-g]indazoles for the treatment of glaucoma |
| US7338972B1 (en) | 2003-12-15 | 2008-03-04 | Alcon, Inc. | Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma |
| US7129257B1 (en) | 2003-12-15 | 2006-10-31 | Alcon, Inc. | Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma |
| US6989445B2 (en) | 2003-12-15 | 2006-01-24 | Alcon, Inc. | Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma |
| US8685924B2 (en) | 2004-08-25 | 2014-04-01 | Takeda Pharmaceutical Company Limited | Preventives/remedies for stress urinary incontinence and method of screening the same |
| WO2006062839A1 (en) | 2004-12-08 | 2006-06-15 | Alcon, Inc. | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma |
| KR100895758B1 (ko) * | 2005-05-03 | 2009-04-30 | 에프. 호프만-라 로슈 아게 | 5-ｈｔ2 리간드로서 테트라사이클릭 아자피라지노인돌린 |
| UA95788C2 (en) | 2005-12-15 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Fused pyrrole derivatives |
| AU2006326067A1 (en) | 2005-12-16 | 2007-06-21 | F. Hoffmann-La Roche Ag | Pyrrolo [2 , 3-b] pyridine derivatives as H3 receptor modulators |
| EP2018863B9 (en) | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
| EP2789338A3 (en) | 2007-11-15 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Condensed pyridine derivate and use thereof |
| US8207165B2 (en) | 2008-03-28 | 2012-06-26 | Nerviano Medical Sciences S.R.L. | 3,4-dihydro-2H-pyrazino[1,2-A]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US20120253036A1 (en) | 2009-12-11 | 2012-10-04 | Yukinori Nagakura | Agent for treating fibromyalgia |
| US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| MX363662B (es) * | 2012-10-08 | 2019-03-27 | Centro De Investig Y De Estudios Avanzados Del I P N Star | Métodos para incrementar la sensibilidad a insulina mediante agonistas de receptores serotonérgicos 5-ht2. |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| JP6217561B2 (ja) * | 2014-08-21 | 2017-10-25 | 信越化学工業株式会社 | 新規オニウム塩化合物及びレジスト組成物並びにパターン形成方法 |
| US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
| KR102622152B1 (ko) * | 2019-10-31 | 2024-01-08 | 홀로스메딕 주식회사 | 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE792724A (fr) * | 1971-12-16 | 1973-06-14 | Merck Patent Gmbh | Derives de pyrazinoindole et leur procede de preparation |
| EP0572863A1 (de) | 1992-06-05 | 1993-12-08 | F. Hoffmann-La Roche Ag | ZNS Pyrazinoindole |
| TW334423B (en) | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
| US5854245A (en) * | 1996-06-28 | 1998-12-29 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| GB9819019D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
| GB9819032D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds IV |
| GB9819035D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Res Ltd | Chemical compounds VII |
| GB9819033D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds VI |
| GB9918962D0 (en) * | 1999-08-11 | 1999-10-13 | Cerebrus Ltd | Chemical compounds xxii |
-
1999
- 1999-01-29 GB GBGB9902047.1A patent/GB9902047D0/en not_active Ceased
-
2000
- 2000-01-28 CN CNB008031398A patent/CN1289499C/zh not_active Expired - Fee Related
- 2000-01-28 KR KR1020017009583A patent/KR100633375B1/ko not_active Expired - Fee Related
- 2000-01-28 JP JP2000596009A patent/JP2002535408A/ja active Pending
- 2000-01-28 MX MXPA01007643A patent/MXPA01007643A/es not_active IP Right Cessation
- 2000-01-28 TR TR2001/02161T patent/TR200102161T2/xx unknown
- 2000-01-28 EP EP00901240A patent/EP1147110B1/en not_active Expired - Lifetime
- 2000-01-28 BR BR0008979-6A patent/BR0008979A/pt not_active Application Discontinuation
- 2000-01-28 ES ES00901240T patent/ES2199132T3/es not_active Expired - Lifetime
- 2000-01-28 AT AT00901240T patent/ATE239731T1/de not_active IP Right Cessation
- 2000-01-28 WO PCT/GB2000/000244 patent/WO2000044753A1/en not_active Ceased
- 2000-01-28 AU AU21196/00A patent/AU758685B2/en not_active Ceased
- 2000-01-28 CN CNB2006100710947A patent/CN100418968C/zh not_active Expired - Fee Related
- 2000-01-28 DK DK00901240T patent/DK1147110T3/da active
- 2000-01-28 DE DE60002554T patent/DE60002554T2/de not_active Expired - Fee Related
- 2000-01-28 US US09/890,186 patent/US6800627B1/en not_active Expired - Fee Related
- 2000-01-28 CA CA002359034A patent/CA2359034A1/en not_active Abandoned
- 2000-01-28 PT PT00901240T patent/PT1147110E/pt unknown
-
2001
- 2001-07-27 ZA ZA200106202A patent/ZA200106202B/en unknown
-
2003
- 2003-08-05 US US10/633,532 patent/US20040039200A1/en not_active Abandoned
- 2003-10-16 US US10/685,799 patent/US7145009B2/en not_active Expired - Fee Related
-
2006
- 2006-03-14 US US11/374,157 patent/US20060160816A1/en not_active Abandoned